What is Eucrates Biomedical Acquisition Corp. (EUCR)?

Eucrates Biomedical Acquisition Corp. (EUCR) is a stock in the Financial Services sector, Shell Companies industry. View full analysis on Stocks360.

What is the current price of EUCR?

The current price of EUCR is $10.04. Prices are updated in real time on Stocks360.

What is EUCR's price-to-earnings (PE) ratio?

EUCR's trailing twelve-month PE ratio is 5.40, based on current price and earnings per share data available on Stocks360.

What is EUCR's market capitalization?

EUCR's market capitalization is $42,228,842.00, placing it in the small-cap tier.

Eucrates Biomedical Acquisition Corp. (EUCR)

Stock analysis · NASDAQ · Financial Services · Shell Companies

$10.04

Market Cap

$42.23M

PE (TTM)

5.40

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.07

Day Range

$10.02 – $10.04

52-wk Range

$9.87 – $10.25

Avg Volume

N/A

Volume

12.70K

Eucrates Biomedical Acquisition Corp. (EUCR) is a publicly traded company in the Financial Services sector. Latest price: $10.04. Market cap $42.23M. Trailing PE 5.40. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Eucrates Biomedical Acquisition Corp.

Eucrates Biomedical Acquisition Corp. currently lacks substantial business operations. Its primary objective is to execute a corporate transaction such as a merger, stock swap, asset purchase, equity acquisition, restructuring, or another comparable strategic alliance involving one or more enterprises. Specifically, it aims to find and acquire a company operating within the life sciences or broader healthcare sectors across North America and Europe. Established in 2020, this entity has its headquarters situated in New York, New York.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	5.40×
P/S (TTM)	0.00×
P/B	3.50×
P/FCF (TTM)	-67.00×
EV / EBITDA	-60.47×
EV / Sales	0.00×
Earnings Yield	18.52%
Free Cash Flow Yield	-1.49%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$42.27M
Net Income (TTM)	$7.82M
Free Cash Flow (TTM)	-$630.29K
Net Debt	$41.20K
Working Capital	$67.06K
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	10.27%
Return on Invested Capital	-5.63%